Understanding the impact of genomic secondary findings on clinical care and patient experience: a protocol for a prospective observational study
Daniel Assamad·Robin Z. Hayeems·Lynette Lau·Dimitri J. Stavropoulos·Olga Jarinova·Stephanie Luca·Martin J. Somerville·KM Boycott·Julie Richer·Laura Zahavich·Anna Szuto·M. Tarnopolsky·Lauren Badalato·Viji Venkataramanan·Michael P. Mackley·Katharine Fooks·Virginie Beauséjour Ladouceur·Meredith Gillespie·Joyce Yan·A. G. Hansen·Lijia Huang·Vercancy Wu·Caitlin Chisholm·Roberto Mendoza-Londono·Erin Hsue·Sarah Sawyer·Salma Shickh·Whiwon Lee·Tugce B Balci·Wendy J Ungar·Christian R. Marshall·Lauren Chad·Chantal F Morel·Anita Villani
This study is approved by the Clinical Trials Ontario (CTO) Research Ethics Review System (REB# CTO 3655). We plan to present our results to academic, patient, clinician and decision-maker audiences through articles and presentations at provincial, national and international meetings.